Regulatory compliance – Page 34

Unreported serial number events during distribution – CAPA and system hardening

“`html Addressing Unreported Serial Number Events During Distribution: A Comprehensive Playbook In pharmaceutical manufacturing and distribution, unreported serial number events pose significant regulatory and operational challenges. These incidents can impact…

CAPA follow-up weak during FDA/EMA inspection – CAPA closure verification

Strengthening CAPA Follow-Up for Enhanced FDA/EMA Inspection Outcomes In pharmaceutical manufacturing and quality assurance, Corrective and Preventive Actions (CAPA) serve as the backbone of quality management systems (QMS). However, persistent…

Analyst training deficiency during sponsor oversight – preventing repeat GLP findings

“`html Addressing Analyst Training Deficiencies Under Sponsor Oversight to Prevent GLP Findings In the field of pharmaceutical development and manufacturing, ensuring compliance with Good Laboratory Practices (GLP) and Good Clinical…

Serialization data mismatch during distribution – recall readiness impact

Tackling Serialization Data Mismatches During Distribution: Ensuring Recall Readiness The challenge of serialization data mismatches during distribution presents a significant obstacle for pharmaceutical manufacturers. Such discrepancies can not only jeopardize…

Validation gaps identified during change control – inspection evidence expectations

Identifying and Addressing Validation Gaps During Change Control for Inspection Readiness Validation gaps occurring during change control represent a critical challenge for pharmaceutical manufacturers. When inadequacies arise in the validation…

Serialization data mismatch during distribution – preventing repeat serialization deviations

Managing Serialization Data Mismatches During Distribution to Prevent Future Deviations Serialization data mismatches can lead to serious consequences in pharmaceutical distribution, including regulatory violations and compromised product integrity. This playbook…

Change impact not assessed during lifecycle management – regulatory deficiency risk

“`html Assessing Change Impact During Lifecycle Management to Mitigate Regulatory Risks In the highly regulated pharmaceutical industry, change management is pivotal to maintaining compliance with Good Manufacturing Practices (GMP). Neglecting…

Unreported serial number events during regulatory inspection – regulatory compliance risk

Addressing Unreported Serial Number Events During Regulatory Inspections In the highly regulated landscape of pharmaceutical manufacturing, unreported serial number events can pose significant compliance risks and operational challenges. Such events,…

Tag: Regulatory compliance

Unreported serial number events during distribution – CAPA and system hardening

CAPA follow-up weak during FDA/EMA inspection – CAPA closure verification

Analyst training deficiency during sponsor oversight – preventing repeat GLP findings

Serialization data mismatch during distribution – recall readiness impact

Validation gaps identified during change control – inspection evidence expectations

Serialization data mismatch during distribution – preventing repeat serialization deviations

Change impact not assessed during lifecycle management – regulatory deficiency risk

Unreported serial number events during regulatory inspection – regulatory compliance risk

Validation gaps identified during system upgrades – inspection evidence expectations

Raw data traceability failure during routine studies – alignment with OECD principles

Unreported serial number events during system integration – preventing repeat serialization deviations

Change impact not assessed during change control – inspection evidence expectations